Novartis plans to continue its slow-motion worldwide restructuring by eliminating around 250 employees, most of which will be in New Jersey.
The state received a WARN letter revealing the company’s intentions.
Novartis said that the most recent layoffs in East Hanover, New Jersey, were caused by its ambitions to centralize its data operations in India, which will have an impact on US employees in Cambridge, Massachusetts, as well as other places.
Novartis has announced plans to eliminate 500 positions in Basel, Switzerland, while hiring 350 “high-tech” employees with superior qualifications.
Several of the roles are located in the multinational’s drug development division.
The cuts have been handed on a piecemeal basis, with the company removing staff around the world.
A 400-person cell and gene therapy unit was disbanded last summer, reintegrating it into the company’s general development activities, and eliminating 120 jobs.
The corporation then made several significant movements in the autumn, expanding its Basel and Cambridge, Massachusetts-based research operations while closing two other locations in China and Switzerland and moving one from Singapore to the Bay Area.
Source: Endpoints News